Co-Authors
This is a "connection" page, showing publications co-authored by Gregory Karczmar and Walter M. Stadler.
Connection Strength
0.915
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
Score: 0.143
-
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8.
Score: 0.108
-
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
Score: 0.103
-
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010 Dec; 257(3):715-23.
Score: 0.095
-
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
Score: 0.086
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.083
-
Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
Score: 0.078
-
Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7.
Score: 0.063
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.062
-
MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
Score: 0.028
-
Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer. World J Radiol. 2011 Oct 28; 3(10):241-5.
Score: 0.026
-
Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med. 2010 Jun; 63(6):1601-9.
Score: 0.023
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.015